Trials / Completed
CompletedNCT04533022
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects With Idiopathic Pulmonary Fibrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Vicore Pharma AB · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | C21 | C21 100 mg BID (twice daily) |
Timeline
- Start date
- 2020-11-13
- Primary completion
- 2024-03-30
- Completion
- 2024-03-30
- First posted
- 2020-08-31
- Last updated
- 2025-05-23
- Results posted
- 2025-05-23
Locations
21 sites across 4 countries: India, Russia, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT04533022. Inclusion in this directory is not an endorsement.